Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
On June 27, 2025 Abeona Therapeutics Inc. (“Abeona”) closed the previously announced sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $155 million in gross cash proceeds under the asset purchase agreement dated May 9, 2025. The voucher had been granted by the FDA on April 28, 2025 following approval of Abeona’s BLA for ZEVASKYN™ (prademagene zamikeracel). The transaction is reported in this Form 8-K under Item 2.01.
In a press release furnished with the filing (Exhibit 99.1) the company disclosed that, including the net PRV proceeds, unaudited cash, cash equivalents, restricted cash and short-term investments stood at approximately $225 million as of June 30, 2025. Management notes the figure is preliminary, unaudited and subject to quarter-end closing procedures; the independent auditor has not reviewed the estimate.
The agreement itself will be filed with Abeona’s forthcoming Form 10-Q. No other material liabilities, guidance changes or pro-forma financials were provided.
The sale injects substantial non-dilutive capital and materially strengthens the company’s liquidity profile while removing the PRV from Abeona’s asset base.